77 completed, 8 terminated, 5 unknown. 45 Phase 4, 24 Phase 3, 11 Phase 1, 5 Not applicable, 5 Phase 2.
Follow insulin glulisine: new trials by email Literature Review of insulin glulisine trials Research Report on insulin glulisine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of Insulin Glulisine (GP40321) Compared to Insulin Glulisine (Apidra® SoloStar®) in Type 1 Diabetes Mellitus Patients GP40321, Apidra® SoloStar®, RinGlar® - Type 1 Diabetes Mellitis | Phase 3 | Completed | Geropharm | 224 | 2023-04-14 | 2025-07-22 |
| Afrezza® INHALE-1 Study in Pediatrics Afrezza, Rapid-acting Insulin Analog, Basal Insulin - Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2 | Phase 3 | Completed | Mannkind Corporation | 319 | 2021-09-29 | 2025-05-06 |
| Super-Bolus: Effects on Postprandial Glycemia After High Glycemic Index Meal Insulin Glulisine, Insulin Aspart, Insulin Lispro - Diabetes Mellitus, Type 1 | Phase 4 | Completed | Medical University of Warsaw | 72 | 2020-01-01 | 2023-11-30 |
| The Impact of Two Different Insulin Dose Calculation on Postprandial Glycemia After Mixed Meal. Insulin Glulisine, Insulin Aspart, Insulin Lispro - Diabetes Mellitus, Type 1 | Phase 4 | Completed | Medical University of Warsaw | 76 | 2019-10-01 | 2025-11-18 |
| Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes (LixiLan-India) INSULIN GLARGINE/LIXISENATIDE (HOE901/AVE0010), INSULIN GLARGINE (HOE901), Metformin - Type 2 Diabetes Mellitus | Phase 3 | Completed | Sanofi | 247 | 2018-06-19 | 2022-04-25 |
| Comparison of Two Treatment Regimens in Patients With Type 2 Diabetes After Short-term Intensive Insulin Therapy INSULIN GLARGINE (HOE901), Insulin Glulisine, Biphasic insulin aspart 30 - Type 2 Diabetes Mellitus | Phase 4 | Completed | Sanofi | 384 | 2018-01-20 | 2022-04-25 |
| Safety and Efficiency of Linagliptin (Trajenta) in the Setting of Internal Medicine Department Linagliptin and Basal Insulin, Basal Insulin and Bolus Insulin - DM2 | Phase 3 | Unknown | Rabin Medical Center | 60 | 2017-10-01 | 2017-09-11 |
| Evaluation of Virtual Versus Traditional Study Conducted in a Group Pilot Study in Adult Patients With Type 1 Diabetes Mellitus (eStudy) Insulin glargine, 300 units per milliliter (U/mL), Background therapy: Rapid Acting meal time insulin analogs (Humalog, Novolog or Apidra) - Type 1 Diabetes Mellitus | Phase 4 | Terminated | Sanofi | 15 | 2017-09-19 | 2022-04-07 |
| Glargine U300 Hospital Trial Glargine U300, Glargine U100, Glulisine Insulin - Type 2 Diabetes | Phase 4 | Completed | Emory University | 247 | 2017-05-17 | 2020-05-07 |
| A Study to Demonstrate Bioequivalence Between Insulin Glulisine U300 and Insulin Glulisine U100 After a Single Subcutaneous Dose Using the Euglycemic Clamp Technique, in Patients With Type 1 Diabetes Mellitus Insulin glulisine (U300), Insulin glulisine, Insulin aspart - Type1 Diabetes Mellitus | Phase 1 | Completed | Sanofi | 44 | 2017-02-17 | 2022-04-25 |
| Impact on the Oxidative Stress of the Different Analogues of Insulin in People With Type 1 Diabetes. (Ineox Study) Toujeo SoloStar, Tresiba, Humalog Kwikpen - Type 1 Diabetes Mellitus | Phase 4 | Completed | Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud | 300 | 2017-01-20 | 2021-12-06 |
| A Study on Comparison of Glargine Plus Glulisine With Premixed Insulin in Type 2 Diabetes Patients Glargine + Glulisine, Premixed analogue insulin (70/30) - Type2 Diabetes | Phase 4 | Completed | India Diabetes Research Foundation & Dr. A. Ramachandran's Diabetes Hospitals | 200 | 2016-12-29 | 2019-09-10 |
| Beneficial Effect of Insulin Glulisine by Lipoatrophy and Type 1 Diabetes (LAS) Apidra, current insulin - Type 1 Diabetes, Lipoatrophy | Phase 4 | Completed | Kinderkrankenhaus auf der Bult | 14 | 2016-09-01 | 2024-10-15 |
| Insulin Requirement for Pure-protein Meal in Children With Type 1 Diabetes on Insulin Pumps. Insulin glulisine, Insulin aspart, Insulin lispro - Diabetes type1 | Phase 4 | Unknown | Medical University of Warsaw | 70 | 2016-02-01 | 2016-07-29 |
| Intranasal Glulisine in Amnestic Mild Cognitive Impairment and Probable Mild Alzheimer's Disease Insulin glulisine, Placebo - Mild Cognitive Impairment, Alzheimer's Disease (AD) | Phase 2 | Terminated | HealthPartners Institute | 49 | 2015-09-28 | 2020-04-09 |
| Dapagliflozin As Additional Treatment To Liraglutide And Insulin In Patients With Type 1 Diabetes Dapagliflozin, Insulin, Liraglutide - Type 1 Diabetes Mellitus | Phase 3 | Completed | University at Buffalo | 26 | 2015-08-01 | 2024-01-24 |
| Investigation of the Safety of Intranasal Glulisine in Down Syndrome Insulin glulisine, Saline - Down Syndrome | Phase 1 | Completed | HealthPartners Institute | 12 | 2015-04-01 | 2019-12-06 |
| Normal Versus Dual Wave Insulin Bolus for High-protein Food insulin aspart, insulin lispro, insulin glulisine - Type 1 Diabetes | Phase 4 | Completed | Medical University of Warsaw | 70 | 2014-10-01 | 2018-01-31 |
| Effect of LIXIsenatide on the Renal System Lixisenatide, Insulin glulisine - Diabetic Kidney Disease, Diabetic Nephropathy | Phase 4 | Completed | Amsterdam UMC, location VUmc | 40 | 2014-09-01 | 2016-04-29 |
| Comparator Trial Using Insulin Glulisine vs. Insulin Lispro for Treatment of Gestational Diabetes NPH, Insulin LISPRO, Insulin glulisine - Diabetes During Pregnancy | Phase 2 | Completed | Sansum Diabetes Research Institute | 17 | 2013-04-01 | 2018-04-18 |
Showing 20 of 90. Sign in to see all of them.
Diabetes Mellitus, Type 2 (39) · Diabetes Mellitus, Type 1 (29) · Diabetes Mellitus (21) · Insulin Resistance (8) · Hyperglycemia (5) · Alzheimer Disease (2) · Cardiovascular Diseases (1) · Cognition Disorders (1) · Cognitive Dysfunction (1) · Diabetes, Gestational (1) · Diabetic Ketoacidosis (1) · Diabetic Nephropathies (1) · Down Syndrome (1) · Fibrosis (1) · Lipodystrophy (1)
Sanofi (45) · Medical University of Warsaw (5) · Emory University (4) · Halozyme Therapeutics (4) · HealthPartners Institute (3) · Cairo University (2) · ikfe-CRO GmbH (2) · Amsterdam UMC, location VUmc (1) · AstraZeneca (1) · Carl T. Hayden VA Medical Center (1) · Centre Hospitalier Universitaire Dijon (1) · Corewell Health West (1) · Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud (1) · Geropharm (1) · Guillermo Umpierrez (1)
United States (32) · Germany (11) · France (7) · Poland (7) · Brazil (6) · Netherlands (6) · United Kingdom (6) · Italy (5) · Mexico (5) · Russia (5) · Spain (5) · Canada (4) · India (4) · South Korea (4) · Argentina (3)
Guillermo Umpierrez, MD (5) · Karen Barch, B.S. (3) · Michael H Rosenbloom, MD (3) · Agnieszka Szypowska (2) · Douglas Muchmore, M.D. (2) · Lisa Jean-Louis (2) · Agnieszka Szypowska, Prof. (1) · Ahmad A Khairy, MD (1) · Ambady Ramachandran, MD,Ph.D,D.Sc (1)
PMID 19366972, PMID 17327353, PMID 18364392, PMID 19487640, PMID 19614946, PMID 19614947, PMID 20199136, PMID 20805258, PMID 21228246, PMID 21324825, PMID 21457066, PMID 21810024, PMID 21812890, PMID 22013886, PMID 22699288, PMID 22851487, PMID 23043164, PMID 23435159, PMID 24170757, PMID 24412929, PMID 24919603, PMID 25168125, PMID 25952532, PMID 26336609, PMID 27490915, PMID 28449402, PMID 30349602, PMID 32077057, PMID 32130661, PMID 32273271, PMID 32738019, PMID 33166419, PMID 33719017, PMID 35351180, PMID 38257156, PMID 41366610
2009 (2), 2008 (1), 2016 (1)